Compare Bandwidth Inc (BAND) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bandwidth Inc vs Novo Nordisk A/S — how do they compare? Bandwidth Inc trades at $51.42 (market cap $1.66B), while Novo Nordisk A/S trades at $46.32 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 125.2× Bandwidth Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Bandwidth Inc pays none. Which is the better fit depends on your goals.
| BAND | NVO | |
|---|---|---|
Market Cap | $1.66B | $207.85B |
Sector | Technology | Health |
52-Week High | $78.44 | $63.98 |
52-Week Low | $12.82 | $35.29 |
Enterprise Value | $2.04B | $222.55B |
Dividend Yield | — | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $52.30, down 0.78% on the day, with strong technical momentum showing bullish moving averages but overbought RSI signals. The company demonstrated solid Q2 2026 performance with EPS of $0.37 beating estimates and 22% revenue growth, driven by AI-driven communications demand and enterprise wins. Analyst sentiment remains overwhelmingly positive with 75% buy ratings and a $75.25 consensus price target representing 44% upside potential.
The outlook appears favorable with accelerating AI adoption and raised 2026 guidance, though valuation remains elevated at 34x EBITDA. Key risks include execution challenges in scaling AI deployments and competitive pressure in cloud communications. Current profitability metrics show improvement but remain thin, requiring sustained growth to justify premium multiples.
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bandwidth Inc
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
